Morbidity and Mortality Weekly Report: Recommendations and Reports, July 3, 2020 / Vol. 69 / No. RR-5

Details

• Alternative Title:
  Prevention of Hepatitis A Virus Infection in the United States : Recommendations of the Advisory Committee on Immunization Practices, 2020
• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
• Personal Author:
  Nelson, Noele P. ; Weng, Mark K. ; Hofmeister, Megan G. ; Moore, Kelly L. ; Doshani, Mona ; Kamili, Saleem ; Koneru, Alaya ; Haber, Penina ; Hagan, Liesl ; Romero, José R. ; Schillie, Sarah ; Harris, Aaron M.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Viral Hepatitis. ; Vanderbilt School of Medicine. Department of Health Policy. ; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. ; University of Arkansas for Medical Sciences. Department of Pediatrics. Section of Pediatric Infectious Diseases.
• Description:
  Hepatitis A is a vaccine-preventable, communicable disease of the liver caused by the hepatitis A virus (HAV). The infection is transmitted via the fecal-oral route, usually from direct person-to-person contact or consumption of contaminated food or water. Hepatitis A is an acute, self-limited disease that does not result in chronic infection. HAV antibodies (immunoglobulin G [IgG] anti-HAV) produced in response to HAV infection persist for life and protect against reinfection; IgG anti-HAV produced after vaccination confer long-term immunity. This report supplants and summarizes previously published recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding the prevention of HAV infection in the United States. ACIP recommends routine vaccination of children aged 12–23 months and catch-up vaccination for children and adolescents aged 2–18 years who have not previously received hepatitis A (HepA) vaccine at any age. ACIP recommends HepA vaccination for adults at risk for HAV infection or severe disease from HAV infection and for adults requesting protection against HAV without acknowledgment of a risk factor. These recommendations also provide guidance for vaccination before travel, for postexposure prophylaxis, in settings providing services to adults, and during outbreaks.
  
  Introduction -- New or Updated Recommendations -- Methods -- HAV Background -- Prophylaxis Against HAV Infection -- Recommendations for Hepatitis A Vaccine and Immune Globulin for Preexposure Prophylaxis -- Future Directions -- Acknowledgments -- Advisory Committee on Immunization Practices.
  
  rr6905a1-H.pdf
  
  
• Subjects:
  Hepatitis A Hepatitis A Vaccines Vaccination
• Source:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 2020; v. 69, no. 5
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  1057-5987 (print) ; 1545-8601 (digital)
• Document Type:
  Journal Issue
• Genre:
  Guideline
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  42 pdf pages
• Volume:
  69
• Issue:
  5
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) Advisory Committee on Immunization Practices (ACIP)
• Main Document Checksum:
  urn:sha-512:9bd0d13cb8c4d92f644374b39569a091dc32ceedb57c2a4cd7f6e7b7d87f5f20a80a8d08ff01f080c55b9cc6926ade774c1926b034cc61ac0db453bc2c808cff
• Download URL:
  https://stacks.cdc.gov/view/cdc/90157/cdc_90157_DS1.pdf
• File Type:
  [PDF - 723.70 KB ]